 Cardiff Oncology Inc NASDAQ: CRDF posted new data from Phase 1b2 trial of onvansertib combined with standard-of-care SOC FOLFIRIbevacizumab for second-line KRAS-mutated metastatic colorectal cancer mCRC. The data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 